Evidence map›Paper›PMID 37963649›Full record

ArticleBMJ open gastroenterology2023

COVID-19 severity is associated with the risk of gastrointestinal bleeding.

Shuji Hibiya, Takashi Fujii, Toshimitsu Fujii, Shinji Suzuki, Mayumi Kondo, Shinya Ooka, Yohei Furumoto, Seishin Azuma, Kei Tanaka, Hitoshi Kurata and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 1 country.

Shuji Hibiya *Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
Takashi Fujii *Department of Gastroenterology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.
Toshimitsu FujiiDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan tfujii.gast@tmd.ac.jp rokamoto.gast@tmd.ac.jp.ORCID 0000-0003-3048-7270
Shinji SuzukiDepartment of Gastroenterology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.
Mayumi KondoDepartment of Gastroenterology, Tokyo Metropolitan Toshima Hospital, Tokyo, Japan.
Shinya OokaDepartment of Gastroenterology, Tokyo Metropolitan Toshima Hospital, Tokyo, Japan.
Yohei FurumotoDepartment of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Seishin AzumaDepartment of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Kei TanakaDepartment of Gastroenterology, Tokyo Metropolitan Otsuka Hospital, Tokyo, Japan.
Hitoshi KurataDepartment of Gastroenterology, Tokyo Metropolitan Otsuka Hospital, Tokyo, Japan.
Shohei TanakaDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Kazuyoshi NagayamaDepartment of Gastroenterology, Tokyo Kyosai Hospital, Tokyo, Japan.
Fumihiko KusanoDepartment of Gastroenterology, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.
Yasuhiro IizukaDepartment of Gastroenterology, Kashiwa Municipal Hospital, Chiba, Japan.
Takahiro KawamuraDepartment of Gastroenterology, JA Toride Medical Center, Ibaraki, Japan.
Hidekazu IkemiyagiDepartment of Gastroenterology, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan.
Shinya SakitaDepartment of Gastroenterology, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan.
Tsunehito YauchiDepartment of Gastroenterology, Soka Municipal Hospital, Saitama, Japan.
Hideki WatanabeDepartment of Gastroenterology, Yokosuka Kyosai Hospital, Kanagawa, Japan.
Ami KawamotoDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
Yusuke MatsuyamaDepartment of Oral Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan.
Kazuo OhtsukaDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
Ryuichi OkamotoDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan tfujii.gast@tmd.ac.jp rokamoto.gast@tmd.ac.jp.
Tokyo Medical and Dental University · JPOtsuka (Japan) · JPYokohama Municipal Minato Red Cross Hospital · JPKure Kyosai Hospital · JPTokyo Metropolitan Bokutoh Hospital · JPTsuchiura Kyodo General Hospital · JPJA Toride Medical Center · JPTokyo Metropolitan Hiroo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe association between the severity of COVID-19 and gastrointestinal (GI) bleeding is unknown. This study aimed to determine whether the severity of COVID-19 is a risk factor for GI bleeding.

designA multicentre, retrospective cohort study was conducted on hospitalised patients with COVID-19 between January 2020 and December 2021. The severity of COVID-19 was classified according to the National Institute of Health severity classification. The primary outcome was the occurrence of GI bleeding during hospitalisation. The main analysis compared the relationship between the severity of COVID-19 and the occurrence of GI bleeding. Multivariable logistic regression analysis was performed to evaluate the association between the severity of COVID-19 and the occurrence of GI bleeding.

results12 044 patients were included. 4165 (34.6%) and 1257 (10.4%) patients had severe and critical COVID-19, respectively, and 55 (0.5%) experienced GI bleeding. Multivariable analysis showed that patients with severe COVID-19 had a significantly higher risk of GI bleeding than patients with non-severe COVID-19 (OR: 3.013, 95% CI: 1.222 to 7.427). Patients with critical COVID-19 also had a significantly higher risk of GI bleeding (OR: 15.632, 95% CI: 6.581 to 37.130). Patients with severe COVID-19 had a significantly increased risk of lower GI bleeding (OR: 10.349, 95% CI: 1.253 to 85.463), but the risk of upper GI bleeding was unchanged (OR: 1.875, 95% CI: 0.658 to 5.342).

conclusionThe severity of COVID-19 is associated with GI bleeding, and especially lower GI bleeding was associated with the severity of COVID-19. Patients with severe or critical COVID-19 should be treated with caution as they are at higher risk for GI bleeding.

Indexed as

COVID-19Gastrointestinal HemorrhageHumansRetrospective StudiesRisk FactorsCOVID-19EPIDEMIOLOGYGASTROINTESTINAL BLEEDING

Identifiers

PMID37963649
PMCPMC10649400
OpenAlexW4388653176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.